Navigation Links
ChemoCentryx Initiates Phase I Clinical Trial of CCX832, the First Small Molecule Inhibitor of ChemR23
Date:1/26/2011

MOUNTAIN VIEW, Calif., Jan. 26, 2011 /PRNewswire/ -- ChemoCentryx, Inc., today announced the initiation of a Phase I clinical trial of CCX832, an orally-administered small molecule that is a potent and selective inhibitor of the chemoattractant receptor, ChemR23.  This receptor is known to regulate inflammatory cells in disease such as psoriasis. CCX832 is the fourth and final drug candidate discovered and developed by ChemoCentryx under the Company's alliance with GlaxoSmithKline (GSK) to identify molecules targeting four specific chemokine and chemoattractant receptors.  The initiation of this Phase I clinical trial triggered a $10 million milestone payment from GSK.

"With the successful conclusion of the discovery phase of our GSK alliance, we are intensifying and expanding our efforts in our other ongoing programs that are entirely outside the GSK alliance," said Thomas J. Schall, Ph.D., President and Chief Executive Officer of ChemoCentryx.  "These programs include a novel drug targeting the chemokine receptor CCR2, which has just successfully completed a Phase 2 clinical trial and a cancer program targeting the receptor CXCR7, which was discovered by ChemoCentryx scientists. In addition, we are advancing programs in liver and kidney disease and in the next generation of medicines for inflammatory bowel disease, all of which offer vast opportunities in largely unmet medical needs."

About ChemR23/CCX832

The ligand for ChemR23, chemerin, is a widely expressed protein that circulates in human plasma in an inactive state and becomes biologically activated in inflammatory settings. There is building evidence that suggests chemerin may serve as a biological alarm signal that, under conditions of tissue injury, recruits ChemR23-expressing immune cells. Diseases such as psoriasis are also associated with elevated levels of activated chemerin. In preclinical studies, CCX832 has demonstrated the ability to successfully block
'/>"/>

SOURCE ChemoCentryx, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. ChemoCentryx to Present at the 29th Annual J.P. Morgan Healthcare Conference
2. ChemoCentryx Reports Positive Phase I Results for CCX168, a Novel C5aR Antagonist, at the Annual American College of Rheumatology Meeting (ACR)
3. ChemoCentryx Reports One-Year Results from PROTECT-1 Study Demonstrating Traficet-ENs Effectiveness in Treating Patients with Crohns Disease at the United European Gastroenterology Federation (UEGW) Meeting
4. ChemoCentryx Reports Positive Results and Completion of Phase I Clinical Studies of Novel CCR2 Antagonist, CCX140, at the European Association for the Study of Diabetes (EASD)
5. ChemoCentryx Reports that Traficet-EN Maintains Remission in Crohns Disease at the Digestive Disease Week (DDW) 2010 Conference
6. ChemoCentryx Initiates Clinical Trial of CCX168, A Novel Small Molecule C5aR Antagonist for the Treatment of Inflammatory and Autoimmune Diseases
7. ChemoCentryx Initiates Phase 2 Clinical Trial of CCX354 for the Treatment of Rheumatoid Arthritis
8. ChemoCentryx Reports Additional New Data from the PROTECT-1 Study Demonstrating Traficet-ENs Effectiveness in Maintaining Remission in Patients with Crohns Disease
9. ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference
10. PROTECT-1 Phase II/III Induction-Stage Results for ChemoCentryxs Traficet-EN(TM) Presented in Oral Session at DDW 2009 Conference
11. ChemoCentryx Completes Enrollment of PROTECT-1, a Phase II/III Clinical Trial of CCR9 Antagonist CCX282-B (Traficet-EN(TM)) in Crohns Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... HILL, N.C. , March 27, 2015  The ... intimidating job description: ensure products meet quality standards at ... budgets and escalating regulations, quality leaders also have the ... and risk. Those who don,t effectively balance ... function as well as marketplace failure and regulatory scrutiny. ...
(Date:3/27/2015)... -- Dynatronics Corporation (NASDAQ: DYNT ) today announced that ... Company,s Board of Directors effective March 23, 2015, to fill ... board member Joseph Barton .  "The ... Directors represents an important step forward for the company," said ... "Rich is a proven leader and is well-known for his ...
(Date:3/27/2015)... -- The Temple Health & Bioscience District (THBD) today announced ... 1802 South First St. in the Temple Medical and Education ... City of Temple to receive funding for redevelopment. ... Veterans Health Care System, the new facility will enable THBD ... and life science companies. Temple ...
Breaking Medicine Technology:New Medical Device Quality Study Finds Regulatory Environment is Boosting Quality Spending, Especially for Large Companies 2Dynatronics Announces Appointment of Richard J. Linder to Board of Directors 2Temple Health & Bioscience District Relocates, Offers Office And Lab Space To Biotech Companies 2
... 26 Healthy Advice ® Networks, the ... consumers and physicians, is pleased to announce they ... award-winning consumer health information once again by the ... such renowned institutions as the Mayo Clinic and ...
... Medco Health Solutions, Inc. (NYSE: MHS ) ... to help protect themselves against certain unnecessary health risks.  The ... of gaps in care that could harm their health and ... was announced today at Medco,s Best Practices Workshop, an annual ...
Cached Medicine Technology:Healthy Advice® Networks Wins 39 National Health Information Awards 2Healthy Advice® Networks Wins 39 National Health Information Awards 3Medco Launches Online Safety Net to Increase Adherence and Prevent Avoidable Medication Risks 2Medco Launches Online Safety Net to Increase Adherence and Prevent Avoidable Medication Risks 3Medco Launches Online Safety Net to Increase Adherence and Prevent Avoidable Medication Risks 4
(Date:3/29/2015)... Youth Villages will participate in a partnership with ... feasibility of implementing a Pay for Success model to ... families. , Third Sector Capital Partners Inc. ran a ... technical assistance throughout 2015 toward a Pay for Success ... chosen by Third Sector. The organization’s work with the ...
(Date:3/29/2015)... North American Seminars receives Texas Board ... Education Courses . , Utilizing Pilates to ... TPTA, approval # 56399TX      , The Interactive ... complex - 10.5 hours - Texas Board of Physical ... Treatment of the SI Joint - 10 hours - ...
(Date:3/28/2015)... Rocket Pure , a manufacturer of ... of their new natural sunscreen. They are offering the ... Both options come with a bonus lip balm sunscreen. , ... Amazon. Click to see the natural sunscreen on ... sunscreen is made with non-nano zinc oxide and provides broad-based ...
(Date:3/28/2015)... March 28, 2015 Could genetic code ... new study by researchers at the Harvard ... with the support of the Coffee and Caffeine Genetics ... Psychiatry this past fall, the study—one of several recent ... genomic data from more than 120,000 regular coffee drinkers ...
(Date:3/28/2015)... 2015 Take a bite of warm, ... action. Acids tumble into the stomach, ready to break ... structure lets these acids run amok, triggering a burning ... symptom. More than 60 million Americans have heartburn at ... heartburn starts, and how it can be stopped. , ...
Breaking Medicine News(10 mins):Health News:Youth Villages Partners with Two Oregon Counties to Advance Pay-for-Success Model to Help At-Risk Youth 2Health News:Youth Villages Partners with Two Oregon Counties to Advance Pay-for-Success Model to Help At-Risk Youth 3Health News:Youth Villages Partners with Two Oregon Counties to Advance Pay-for-Success Model to Help At-Risk Youth 4Health News:Rocket Pure Releases New Natural Sunscreens For Athletes 2Health News:Rocket Pure Releases New Natural Sunscreens For Athletes 3Health News:How Coffee Habits Relate to Our Genetic Code and Enhancing the Caffeine Experience 2Health News:How Coffee Habits Relate to Our Genetic Code and Enhancing the Caffeine Experience 3Health News:Bypass Your Heartburn Worries This Easter With Tylers Coffee 2
... Jerusalem, Nov. 9, 2009 Research carried out among thousands ... a loss of bone mass, leading to osteoporosis and fractures. ... researchers, Prof. Raz Yirmiya, head of the Brain and Behavior ... They further revealed that the relationship between depression and bone ...
... SAN DIEGO, Nov. 9 Renewal Laboratories announced today ... produce functional beverages with important anti-oxidants and omega3 fatty ... Q10, resveratrol, and omega3 fish oil may now be ... company will soon premier a unique line of all ...
... Doctor house calls now ... ... pain management physician, will now offer routine house calls to residents of Manhattan in New York ... at 212-918-1629 or sending an email from davisbregman.com . The convenience of being able to ...
... ... both CAMTS and EURAMI accreditation and Department of Defense approval, , ... Birmingham, AL (PRWEB) November 9, 2009 ... full accreditation from the European Aero-Medical Institute (EURAMI). EURAMI is a Stuttgart, Germany, ...
... Bregman , a pain management physician will now offer routine house ... be able to request a house call by ... davisbregman.com . The convenience of being able to see the ... this new way of seeing most patients. The service will be ...
... O,Brien, president of Catholics for Choice, issued the following statement ... recent weeks tells us and the American voters a lot ... to our core values, seeking to overcome the struggles ordinary ... cannot afford basic healthcare or have to choose between maintaining ...
Cached Medicine News:Health News:Connection between depression and osteoporosis detailed by Hebrew University researchers 2Health News:Renewal Laboratories(TM) Announces the First Omega3 Supplement Water for Cardiac Health 2Health News:Davis Bregman MD Now Offering House Calls in Manhattan 2Health News:AirMed International, Top U.S. Air Ambulance, Receives EURAMI Accreditation 2Health News:Davis Bregman MD Now Offering House Calls in Manhattan 2Health News:Catholics for Choice Statement on Healthcare Reform Bill 2
Determination of Prothrombin Time (PT) by STA Analyzers (ISI~1.3).Freeze-dried rabbit brain thromboplastin with heparin inhibitor....
For the quantitative in vitro determination of creatinine in serum, plasma or urine....
For the quantitative in vitro determination of Magnesium in serum, plasma and urine...
For the quantitative in vitro determination of Anti-Streptolysin-O (ASO) in serum...
Medicine Products: